Aptus Pharma Limited filed a regulatory statement confirming no deviations in utilization of ₹13.02 crore IPO proceeds raised on September 29, 2025.
All funds were fully utilized as per original objects: ₹16.295 lakh for capex, ₹8 crore for working capital, ₹1.9105 crore for corporate purposes, and ₹1.48 crore for issue expenses.
The Audit Committee reviewed and approved the utilization statement on April 27, 2026, with monitoring by CARE Rating Agency.